Koers GENFIT Euronext Paris
Aandelen
GNFT
FR0004163111
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- PTS | - |
Omzet 2024 * | 89,63 mln. 95,84 mln. 0 | Omzet 2025 * | 48,78 mln. 52,16 mln. 0 | Marktkapitalisatie | 160 mln. 171 mln. 0 |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 15 mln. 16,04 mln. - | Nettowinst (verlies) 2025 * | -21 mln. -22,45 mln. - | EV/omzet 2024 * | 1,47 x |
Nettoliquiditeiten 2024 * | 27,6 mln. 29,51 mln. 0 | Nettoliquiditeiten 2025 * | 44,9 mln. 48,01 mln. 0 | EV/omzet 2025 * | 2,35 x |
K/w-verhouding 2024 * |
6,83
x | K/w-verhouding 2025 * |
24,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,77% |
Recentste transcriptie over GENFIT
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 01-05-18 |
Founder | 68 | 01-09-99 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 22-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 04-03-21 | |
Founder | 68 | 01-09-99 | |
Founder | 52 | 15-09-99 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |
- Beurs
- Aandelen
- Koers GNFT
- Koers GNFT